Skip to content
Home/Companies/Biotech/Attgeno

Attgeno

Biotech·Sweden·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Attgeno?

Attgeno is a Swedish Biotech company, currently owned by Eir Ventures since 2022.

Hand-verified · updated 2026-08-17

Open JSON · CC-BY
Eir Ventures
Investor
Eir Ventures
Eir Ventures I · 2020 · Life Sciences VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Eir Ventures I

Other portfolio companies in the same fund.

Moleculent
Active
BiotechSweden· 2024
Purpose Pharma
Active
PharmaSweden· 2024
Dania Tx
Active
BiotechDenmark· 2023
GutCRINE
Active
BiotechDenmark· 2023
RAPP
Active
HealthTechSweden· 2023
Scenic Biotech
Scenic Biotech
Active
BiotechNetherlands· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Attgeno?

Attgeno is currently owned by Eir Ventures, through Eir Ventures I, since 2022.

When did Eir Ventures acquire Attgeno?

Eir Ventures acquired Attgeno in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue